Immune responses in patients with esophageal cancer treated with SART1 peptide‑pulsed dendritic cell vaccine

  • Authors:
    • Miwako Narita
    • Tatsuo Kanda
    • Takashi Abe
    • Takayoshi Uchiyama
    • Minami Iwafuchi
    • Zhiyin Zheng
    • Aichun Liu
    • Tsutomu Kaifu
    • Shinichi Kosugi
    • Masahiro Minagawa
    • Kyogo Itoh
    • Masuhiro Takahashi
  • View Affiliations

  • Published online on: January 23, 2015     https://doi.org/10.3892/ijo.2015.2846
  • Pages: 1699-1709
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients with advanced stage of squamous cell carcinoma of esophagus have a poor prognosis with a lethal outcome. In order to explore the feasibility and effectiveness of dendritic cell (DC)‑based immunotherapy for squamous cell carcinoma of esophagus, we performed a phase Ⅰ/Ⅱ clinical trial of monocyte‑derived dendritic cells (moDCs) pulsed with SART1 peptide in seven patients with advanced stage of this disease. Although the feasibility of this therapy was definite, the effectiveness was not clearly confirmed in advanced stage of squamous cell carcinoma of esophagus. However, in vitro study revealed that moDCs generated for this therapy possessed a potent ability of inducing SART1 peptide‑specific cytotoxic T lymphocytes (CTLs). In addition, these moDCs were demonstrated to be able to produce exosomes with an antigen presenting ability for inducing SART1 peptide‑specific CTLs. ELISPOT assay using cryopreserved patient's lymphocytes demonstrated that IFN‑γ ELISPOTs were increased after four times of SART1 peptide‑pulsed moDC vaccinations compared with before the vaccination in a patient. The present study demonstrated that moDCs prepared from advanced stage of squamous cell carcinoma of esophagus possess a good immune function and in vivo immune responses (detected by ELISPOT assay) were evoked by the infusion of these moDCs. These findings suggest that DC‑based immunotherapy could be one of the modalities applicable for squamous cell carcinoma of esophagus.
View Figures
View References

Related Articles

Journal Cover

April-2015
Volume 46 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, Liu A, Kaifu T, Kosugi S, Minagawa M, Minagawa M, et al: Immune responses in patients with esophageal cancer treated with SART1 peptide‑pulsed dendritic cell vaccine. Int J Oncol 46: 1699-1709, 2015
APA
Narita, M., Kanda, T., Abe, T., Uchiyama, T., Iwafuchi, M., Zheng, Z. ... Takahashi, M. (2015). Immune responses in patients with esophageal cancer treated with SART1 peptide‑pulsed dendritic cell vaccine. International Journal of Oncology, 46, 1699-1709. https://doi.org/10.3892/ijo.2015.2846
MLA
Narita, M., Kanda, T., Abe, T., Uchiyama, T., Iwafuchi, M., Zheng, Z., Liu, A., Kaifu, T., Kosugi, S., Minagawa, M., Itoh, K., Takahashi, M."Immune responses in patients with esophageal cancer treated with SART1 peptide‑pulsed dendritic cell vaccine". International Journal of Oncology 46.4 (2015): 1699-1709.
Chicago
Narita, M., Kanda, T., Abe, T., Uchiyama, T., Iwafuchi, M., Zheng, Z., Liu, A., Kaifu, T., Kosugi, S., Minagawa, M., Itoh, K., Takahashi, M."Immune responses in patients with esophageal cancer treated with SART1 peptide‑pulsed dendritic cell vaccine". International Journal of Oncology 46, no. 4 (2015): 1699-1709. https://doi.org/10.3892/ijo.2015.2846